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Purpose or Objective 
To analyze the tolerance in the French randomized phase 
3 trial (BONBIS) that investigated the role of the boost to 
the tumor bed after breast-conserving surgery for ductal 
carcinoma in situ (DCIS). 
Material and Methods 
From November 2008 to July 2014, 2004 DCIS patients 
were treated by tumorectomy followed by whole-breast 
irradiation (WBI) to a dose of 50 Gy in 25 fractions for 5 
weeks. Patients were randomized after surgery and before 
WBI between an additional boost to the primary tumor bed 
(16 Gy in 8 fractions of 2 Gy, n=1002) and no further 
treatment (n=1002). Stratification factors were centre, 
age (below or above40), hormonotherapy (yes or no), 
histological grade (low or intermediate or high), diagnosis 
mode (clinically or by mammography), surgical margins (1-
2 mm vs 3 mm). Acute toxicities were prospectively 
recorded from baseline to 3 months after radiotherapy 
completion.  
Results 
A total of 1928 DCIS patients were evaluable for acute 
tolerance. Median age was 57 years. Re-excision was 
needed in 20% of patients in each treatment arm, mainly 
due to involved margins orpostoperative complications. 
Median time for radiotherapy initiation was 54 days from 
surgery [min; max=5; 146]. Mean volumes of breast (CTV1) 
and of boost (CTV2) were 545 cc [min; max= 6; 2818] and 
25 cc [min; max= 0; 754], respectively. A significant higher 
rate of radiotherapy disruption was observed in boost arm 
(3.9% vs 1.5%; p=0.015) due to acute toxicities occurrence 
with a mean time of disruption of 3 days. A significantly 
higher rate of grade ≥2 overall toxicities (including skin, 
edema, pain) was observed in the boost arm (54.6% vs 
36.4%; p<0.001). Similarly, grade 3 erythema was 
significantly increased in the boost arm (5.4% vs 2.1%; 
p<0.001).  
Conclusion 
In the boost arm, a higher rate of grade ≥2 acute toxicities 
was observed compared to the control arm. However, 
grade 3 erythema was quite low even though its 
occurrence was significantly higher in the boost arm. A 
multivariate analysis of acute toxicities will be presented 
at the congress.  
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Purpose or Objective 
Seroma describes collection of serous fluid within a cavity 
and can occur following breast surgery. A seroma 
prevalence of 37-57% has been reported. Seroma is 
associated with adverse effects (AE) following breast 
radiotherapy. These AE have been predominantly assessed 
by clinicians and photographs, and not by patients. This 
study investigates if seroma is associated with patient-
reported AE in IMPORT HIGH (CRUK/06/003).  
Material and Methods 
IMPORT HIGH (ISRCTN47437448) is a randomised, multi-
centre phase III trial testing dose-escalated simultaneous 
integrated boost against sequential boost each delivered 
by intensity modulated radiotherapy (RT) in women with 
breast cancer. AE assessment included patient-reported 
outcome measures (PROMs) in a planned sub-set of 
patients. A case-control methodology was used to 
investigate the association of seroma with patient-
reported AEs at 3 years. Cases were patients who reported 
moderate/marked breast appearance change and controls 
were those who reported none/mild changes. One control 
was selected at random for each case (unmatched). 
Seromas were identified on RT CT planning scans and 
graded as not visible/subtle or visible/highly visible. 
Logistic regression models were used to test associations 
between seroma and moderate/marked breast 
appearance change at 3 years, adjusting for patient and 
tumour/treatment factors. Tumour and treatment factors 
were reported by clinicians.  
Results 
2621 patients were recruited to IMPORT HIGH. 1078/1149 
patients at centres participating in the PROMs sub-study 
consented to PROMs. 836 patients responded to whether 
they had breast appearance change at 3 years, of whom 
231 (28%) patients reported moderate/marked changes 
(cases); 231 controls were identified. RT CT planning data 
were available for 202 cases and 205 controls. 156/231 
(68%) cases and 148/231 (64%) controls received 
chemotherapy respectively. Seroma prevalence was 
41/202 (20%) in cases and 32/205 (16%) in controls. No 
significant association was found between visible seroma 
and moderate/marked breast appearance change [odds 
ratio 1.38 (95% confidence interval 0.83-2.29), p=0.22] 
regardless of chemotherapy use. Larger seroma volume 
was significantly associated with worse breast appearance 
change on univariate analysis only [1.21 (1.02-1.44), 
p=0.03]. Treatment group was not significant on 
univariate analysis. On multivariable analysis, 
independent risk factors for worse breast appearance 
change were larger tumour size [1.43 (1.13-1.82), 
p=0.003], haematoma [5.96 (2.20-16.11), p<0.001], 
current smoking [2.25 (1.06-4.74), p=0.03] and body 
image concerns at baseline [1.04 (1.00-1.09), p=0.04].  
Conclusion 
Seroma prevalence in this study was lower than previously 
reported, perhaps reflecting the proportion of patients 
receiving chemotherapy in whom seroma resolves. Seroma 
was not associated with patient-reported breast 
appearance change but haematoma was a significant risk 
factor. Smoking cessation pre-radiotherapy should be 
encouraged to reduce AE. 
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Purpose or Objective 
Recent studies have demonstrated a dose-effect 
relationship between radiation dose to the heart and the 
risk of an acute coronary event (ACE). However, 
knowledge on the exact underlying mechanisms behind 
this radiation-induced cardiac toxicity is lacking. Such 
information is crucial for the development of new 
strategies to optimize radiotherapy (RT) treatment 
planning.  
We hypothesized that radiation dose to atherosclerotic 
plaques leads to subsequent inflammatory reactions and 
increased risk of ACEs. Thus, dose to the plaques may be 
a stronger predictor of an ACE after RT than the dose to 
the left anterior descending coronary artery (LAD). 
Therefore, the aim of this study was to investigate the 
association between radiation dose to the LAD and the 
LAD-plaques and the risk of an ACE in breast cancer (BC) 
patients treated with 3D conformal radiation therapy. 
Material and Methods 
The study cohort consisted of 952 BC patients treated with 
postoperative RT after breast conserving surgery. The LAD 
was delineated using an auto-segmentation tool. After 
calculation of the coronary artery calcium score, LAD-
plaques with Hounsfield units ≥130 were manually 
delineated. The primary endpoint was the cumulative 
incidence of an ACE (defined according to Darby et al.) 9 
years after treatment. For each individual patient, the 
mean heart dose (MHD), mean dose to the LAD and the 
mean dose to the LAD-plaques were collected from 
planning CT scans. 
First, the relation between the dose to the LAD and the 
LAD-plaques and ACEs was analyzed with an univariable 
Cox-regression analysis. Then, an association analysis 
using a Cox-regression model was performed, only 
including patients who had a LAD-plaque. Furthermore, 
we used a multivariable Cox-regression analysis to 
calculate the excess risk of an ACE per patient including 
age, cardiac risk factors (0 or ≥1) and mean dose to the 
heart and LAD-plaques. 
Results 
The median follow-up time was 7.5 years (range: 0.1-10.1 
years). In total, 31 patients developed an ACE during 
follow-up. 167 patients (17.5%) had a LAD-plaque. 
Univariable Cox-regression analysis showed that the 
impact of the dose to the LAD-plaque was much stronger 
than the impact of the MHD and the mean dose to the LAD 
(Figure 1). A significant but modest association between 
radiation dose to the LAD and ACEs was found (regression 
coefficient 0.053 (95% CI 1.014-1.096), P=0.008). 
However, a much stronger and significant association was 
found between the mean dose to the LAD-plaques and 
ACEs (regression coefficient 0.323 (95% CI 1.129-1.689), 
P=0.002). In figure 2, the NTCP-curves are shown for a 50-










The results of this study suggest that mean dose to the 
atherosclerotic plaque in the LAD is more important for 
the development of an ACE in BC patients than the MHD, 
possibly due to radiation-induced inflammatory reactions 
in pre-existent plaques. This will be further investigated. 
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Purpose or Objective 
Quality indicators (QI) are measurement tools that can be 
used as guides to evaluate and improve overall quality of 
patient care . Monitoring QIs amongst departments allows 
for clinical practice benchmarking leading to exchange of 
best practice and the delivery of best-quality 
care.  Mandated by the Belgian Federal Government, 
radiotherapy (RT) specific structural, process and 
outcome indicators were defined in a collaboration of the 
College for Physicians in Radiation Oncology (RO) in 
Belgium and the Belgian Quality Managers (QM) in 
radiotherapy Association (QMRT.be). Subsequently, a 
voluntary national QI data collection started, with the aim 
of generating benchmarking reports and supporting 
departmental and national quality improvement projects. 
Material and Methods 
The QI were defined through a simplified Delphi approach 
by a panel of RO, QM and medical physics experts 
following the national requirement to collect quantitative 
data annually (e.g. number of treatments) but also based 
on established guidelines or good practice. As such, 18 
structural (e.g. number of equipment and treatment 
activities), 30 process (e.g. timely delivery) and 6 
outcome QIs (recorded acute toxicity related to treatment 
for breast, head-and-neck and prostate cancer patients) 
have been defined. To evaluate the feasibility of data 
collection in all Belgian RT departments, a test phase was 
launched in 2015, collecting the full set of structural QIs, 
but limiting the number of patient-specific QIs (n=5 per 
pathology/department). Upon validation of this dummy 
run, as of 2016, a broader capture of process and outcome 
QIs was started (n=25 patients/pathology/department). 
Results 
A high department participation rate to this national QI 
project was obtained, with 100% of departments 
participating in 2015 and 2016 and 92% in 2017. This 
success rate is highly attributed to the presence of QM in 
each RT department.  Over the 3 year-period, 33.993 data 
points were collected contributing to the establishment of 
the 54 QIs. The analysis of the collected QIs gave insight 
into national activity levels, resource availability, clinical 
practice and acute toxicity levels. This resulted in a yearly 
global report but also in the generation of individualized 
benchmarking documents in which each department is 
able to identify its performance as compared to other 
departments which are anonymously identified (see fig 1). 
